Injectable calcium-phosphate-based composites for skeletal bone treatments.

Current research in bone regeneration focuses on injectable materials that can adapt to complex defect geometries. Established knowledge shows that calcium-phosphate cements offer biocompatibility and shape adaptation. However, a gap remains in achieving optimal injectability and mechanical properties. Prior research has shown that hydroxyapatite supports bone integration, but setting times and mechanical behavior remain limiting factors. This uncertainty drove the need to explore composite materials. No prior work had resolved the balance between injectability and structural integrity. The integration of hydrogels into bone cements is a novel approach. This paper's contribution lies in evaluating how PVA affects cement properties. The study addresses the need for better injectable bone substitutes.

The study aimed to assess how adding poly(vinyl alcohol) (PVA) affects the performance of injectable bone cements. The specific problem is the need for materials that can be easily injected but still harden effectively. The motivation stems from limitations in current cements, such as short injectability windows. The goal was to improve setting and hardening properties. The researchers also wanted to test the material's in vivo behavior. They focused on injectability time and mechanical performance. The study aimed to compare bone healing outcomes between cements with and without PVA. The results could inform the design of better bone substitutes.

The researchers used a composite of alpha-tricalcium phosphate and hydroxyapatite. They added a poly(vinyl alcohol) hydrogel phase to the cement mixture. The cement composition was 98% alpha-tricalcium phosphate and 2% hydroxyapatite. They evaluated the setting and hardening properties of the composite. The injectability time was measured to assess practical usability. In vivo tests were conducted using a rabbit model with critical size defects. Histological analysis was performed on bone-composite interfaces. Microhardness and histomorphometric data were collected to assess bone growth.

The addition of PVA significantly increased the injectability time from minutes to one hour. The setting and hardening properties were modulated by the hydrogel phase. In vivo tests showed enhanced bone healing in trabecular tissue. Histological results revealed greater new tissue deposition at bone-composite interfaces. After 12 weeks, the composite outperformed plain cement in tissue integration. Microhardness analysis confirmed better bone quality in composite-treated areas. Histomorphometric data showed higher bone formation in composite implants. The composite demonstrated superior performance at both evaluation times.

The authors propose that PVA improves the injectability and setting properties of bone cements. The composite's ability to enhance bone healing was confirmed in vivo. The histological findings suggest better integration at bone-composite interfaces. The study supports the use of PVA-modified cements for bone defect reconstruction. The results indicate that the composite promotes higher bone formation than plain cement. The mechanical and biological benefits of the composite are attributed to the PVA phase. The findings suggest that PVA can be used to tailor cement properties for clinical use. The authors suggest that this approach could lead to more effective bone substitutes.